Drug Trial Radar · NCT02580370
Safety and Efficacy of Botulinum Toxin Type A Topical Gel for Lateral Canthal Lines
Last checked: Nov 20, 2026Latest source record: Sep 9, 2016 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
450
Actual
Start
Sep 2015
Primary completion
Jul 2016
Study completion Aug 2016
Sponsor
- Lead sponsor
- Revance Therapeutics, Inc.Industry
- Sponsor type
- Industry
- First posted
- Oct 20, 2015
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a safety and efficacy study of botulinum toxin type A in subjects with lateral canthal lines.
Conditions
- Skin Aging
Interventions
Botulinum toxin type ABiological
Topical botulinum toxin type A
Placebo comparatorBiological
Topical placebo comparator
Primary outcomes
What the sponsor says the trial is designed to measure.
- Composite endpoint based upon the investigator global assessment (IGA-LCL) and patient assessment of severity (PSA) of lateral canthal linesTime frame: Week 4
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Site not named
Coral Gables, Florida
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.